Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Successful Phase 3 Trial for Belatacept

May 3, 2010 6:26 am | News | Comments

Two-year results from phase 3 clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.


Study Implicates Rewired Interactions In Cancer

May 3, 2010 6:07 am | News | Comments

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships.


New Tool Enables Wider Analysis Of Deep Sequencing

May 3, 2010 6:04 am | News | Comments

Scientists seeking to understand the machinations of the proteins behind genetics have a powerful new tool at their disposal, courtesy of researchers at the Stanford University School of Medicine.


Pitt Researchers Explain Omega-3 Abilities

May 3, 2010 5:57 am | News | Comments

Scientists at the University of Pittsburgh School of Medicine have located a group of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes.


McNeil Issues Children's Medicine Recall

May 3, 2010 5:49 am | News | Comments

The Food and Drug Administration is investigating a health-care company for possible other problems following its recall of more than 40 over-the-counter infant's and children's liquid medications.


FDA Approves Breakthrough Cancer Therapy Provenge

April 30, 2010 10:30 am | by Matthew Perrone, AP Business Writer | News | Comments

Dendreon Corp.'s Provenge, a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.


Simulation Software

April 30, 2010 7:08 am | Product Releases | Comments

The time-consuming scientific research behind drug discovery can now be accelerated with the launch of AMBER 11, a software tool that enables bio-scientists to harness the power of supercomputing on their desktop PC.


Biomarker Panel

April 30, 2010 6:46 am | Product Releases | Comments

Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry.


Commentary: Will Provenge Be New Standard of Care?

April 30, 2010 6:36 am | by Fleur Pijpers, Senior Analyst, Datamonitor | News | Comments

Despite FDA approval, it remains to be seen how frequently Provenge will be used in castration-resistant prostate cancer (CRPC), according to a Datamonitor analyst.


CEVEC and Aragen Sign Strategic License Agreement

April 30, 2010 6:29 am | News | Comments

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California-based contract research and development organization, have signed of a strategic license agreement.


Mallinckrodt Baker Signs Deal With VWR International

April 30, 2010 6:17 am | News | Comments

Covidien announced that its Mallinckrodt Baker business unit has entered into a multi-year agreement with global laboratory supply company, VWR International, LLC, to distribute Mallinckrodt Baker’s J.T.Baker brand products in Eastern and Central Europe.


All Immunosuppressive Drugs Carry Same Cancer Risk

April 30, 2010 6:11 am | News | Comments

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).


University Finds MS Biomarkers A Decade Before Symptoms

April 30, 2010 6:07 am | News | Comments

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled.


FDA Approves Once-Daily Kaletra

April 30, 2010 5:56 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved once-daily dosing of Kaletra for adult patients with HIV who have previously taken antiretroviral therapy.


Provenge Vaccine Receives FDA Approval

April 30, 2010 5:45 am | by Matthew Perrone | News | Comments

A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.